114 related articles for article (PubMed ID: 38522759)
1. The ADAM17 inhibitor ZLDI-8 sensitized hepatocellular carcinoma cells to sorafenib through Notch1-integrin β-talk.
Xu C; Gao X; Ren T; Geng H; Yang K; Huang Y; Zhang W; Hou S; Song A; Zhang Y; Zhao Q
Pharmacol Res; 2024 May; 203():107142. PubMed ID: 38522759
[TBL] [Abstract][Full Text] [Related]
2. Novel ADAM-17 inhibitor ZLDI-8 inhibits the metastasis of hepatocellular carcinoma by reversing epithelial-mesenchymal transition in vitro and in vivo.
Lu HY; Chu HX; Tan YX; Qin XC; Liu MY; Li JD; Ren TS; Zhang YS; Zhao QC
Life Sci; 2020 Mar; 244():117343. PubMed ID: 31978449
[TBL] [Abstract][Full Text] [Related]
3. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells.
Zhang Y; Li D; Jiang Q; Cao S; Sun H; Chai Y; Li X; Ren T; Yang R; Feng F; Li BA; Zhao Q
Cell Death Dis; 2018 Jul; 9(7):743. PubMed ID: 29970890
[TBL] [Abstract][Full Text] [Related]
4. Novel ADAM-17 inhibitor ZLDI-8 inhibits the proliferation and metastasis of chemo-resistant non-small-cell lung cancer by reversing Notch and epithelial mesenchymal transition in vitro and in vivo.
Lu HY; Zu YX; Jiang XW; Sun XT; Liu TY; Li RL; Wu Q; Zhang YS; Zhao QC
Pharmacol Res; 2019 Oct; 148():104406. PubMed ID: 31442576
[TBL] [Abstract][Full Text] [Related]
5. A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo.
Li DD; Zhao CH; Ding HW; Wu Q; Ren TS; Wang J; Chen CQ; Zhao QC
Cell Prolif; 2018 Oct; 51(5):e12480. PubMed ID: 30069943
[TBL] [Abstract][Full Text] [Related]
6. ADAM17 promotes cell migration and invasion through the integrin β1 pathway in hepatocellular carcinoma.
Li Y; Ren Z; Wang Y; Dang YZ; Meng BX; Wang GD; Zhang J; Wu J; Wen N
Exp Cell Res; 2018 Sep; 370(2):373-382. PubMed ID: 29966664
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells.
Liu J; Yang X; Liang Q; Yu Y; Shen X; Sun G
Int J Biochem Cell Biol; 2020 Sep; 126():105820. PubMed ID: 32750425
[TBL] [Abstract][Full Text] [Related]
8. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
9. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
Xia P; Zhang H; Xu K; Jiang X; Gao M; Wang G; Liu Y; Yao Y; Chen X; Ma W; Zhang Z; Yuan Y
Cell Death Dis; 2021 Jul; 12(7):691. PubMed ID: 34244479
[TBL] [Abstract][Full Text] [Related]
10. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
Zhou Y; Huang Y; Dai T; Hua Z; Xu J; Lin Y; Han L; Yue X; Ho L; Lu J; Ai X
Biomed Pharmacother; 2021 Jan; 133():111030. PubMed ID: 33378944
[TBL] [Abstract][Full Text] [Related]
11. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
13. NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner.
Li H; Lan T; Xu L; Liu H; Wang J; Li J; Chen X; Huang J; Li X; Yuan K; Zeng Y; Wu H
J Exp Clin Cancer Res; 2020 Jul; 39(1):128. PubMed ID: 32631394
[TBL] [Abstract][Full Text] [Related]
14. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
15. Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-Myc pathway.
Sun L; He M; Li F; Wu D; Zheng P; Zhang C; Liu Y; Liu D; Shan M; Yang M; Ma Y; Lian J; Xiong H
Hepatol Commun; 2024 Apr; 8(4):. PubMed ID: 38573832
[TBL] [Abstract][Full Text] [Related]
16. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB
J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268
[TBL] [Abstract][Full Text] [Related]
17. PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma.
Wang P; Jiang Z; Liu X; Yu K; Wang C; Li H; Zhong L
Cancer Med; 2020 Oct; 9(19):6972-6983. PubMed ID: 32779397
[TBL] [Abstract][Full Text] [Related]
18. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
Nagai T; Arao T; Furuta K; Sakai K; Kudo K; Kaneda H; Tamura D; Aomatsu K; Kimura H; Fujita Y; Matsumoto K; Saijo N; Kudo M; Nishio K
Mol Cancer Ther; 2011 Jan; 10(1):169-77. PubMed ID: 21220499
[TBL] [Abstract][Full Text] [Related]
20. Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
Ou DL; Lee BS; Chang YC; Lin LI; Liou JY; Hsu C; Cheng AL
PLoS One; 2013; 8(6):e66589. PubMed ID: 23818948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
